Patent holdings for IPC class C07D 211/40

Total number of patents in this class: 115

10-year publication summary

10
5
8
8
7
5
6
8
10
3
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
FMC Corporation
847
5
Theravance Biopharma R&D IP, LLC
460
5
ChemoCentryx, Inc.
387
4
F. Hoffmann-La Roche AG
7934
3
AstraZeneca AB
2928
3
Amgen Inc.
4071
3
Bristol-myers Squibb Company
4879
2
Board of Regents, The University of Texas System
5763
2
ABAC Therapeutics S.L.
7
2
Athenex, Inc.
26
2
Neurocrine Biosciences, Inc.
409
2
Nippon Soda Co., Ltd.
894
2
Sirna Therapeutics, Inc.
111
2
Idorsia Pharmaceuticals Ltd.
350
2
Shanghai Meizer Pharmaceuticals Co., Ltd.
14
2
Vividion Therapeutics, Inc.
34
2
ReNAgade Therapeutics Management Inc.
44
2
Hong Kong King-friend Industrial Company Ltd.
40
2
Hoffmann-La Roche Inc.
3404
1
BASF SE
20892
1
Other owners 66